Gene Therapy
The future of CAR-T therapy in ALL
Acute lymphoblastic leukemia (ALL) is an aggressive and heterogeneous disease with a high mortality rate. However, several advances have been…
Date: 20th July 2022
An insight into novel targets in myeloma and mechanisms of resistance to PIs and IMiDs
Multiple myeloma has seen many advances in recent years, and novel targeted agents are transforming the field. Several immunotherapies, including…
Date: 15th July 2022
Impact of the COVID-19 pandemic on the EBMT & projects in the pipeline
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), which took place on 19-23 March…
Date: 3rd June 2022
CAR-T and lymphoma treatment in the UK
Lymphoma treatment has seen many recent advances, with CAR-T therapy being a game changer for patients. Several clinical trials investigating…
Date: 27th May 2022
Harnessing the power of immunotherapy in myeloma and amyloidosis
The myeloma treatment landscape has seen a lot of progress in the last few years, with several novel therapies emerging,…
Date: 20th May 2022
Genomics in the age of immuno-oncology
Immunotherapies are at the forefront of myeloma treatment and there are many questions remaining. Defining high-risk is important when making…
Date: 29th April 2022
ASH 2021: what did ASH 2021 mean for MDS?
With high rates of relapse in patients with myelodysplastic syndromes (MDS), there is a great unmet need for novel treatments…
Date: 18th March 2022
ASH 2021: the future of cell therapies in lymphoma
Cell therapies including chimeric antigen receptor (CAR) T-cell therapy represent novel treatments for patients with lymphoma, especially for those who…
Date: 25th February 2022
The Lymphoma Sessions: post-ASH 2021
The 63rd American Society of Hematology (ASH) annual meeting saw a plethora of updates in lymphoma. While most of them…
Date: 2nd February 2022
COSTEM: the role of alloHSCT in ALL
Over the past few years, the therapeutic landscape for acute lymphoblastic leukemia (ALL) has dramatically evolved, with the development of…
Date: 25th October 2021
IACH 2021: CAR-T in clinical practice
Currently, five chimeric antigen receptor T-cell (CAR-T) therapies are approved for the treatment of hematological malignancies including acute lymphoblastic leukemia,…
Date: 30th September 2021
CAR-T vs bispecifics: replacing ASCT in myeloma
Autologous stem cell transplantation (ASCT) has been the standard of care patients with multiple myeloma for the past three decades;…
Date: 17th September 2021
